Scroll.in The Jan Vishwas Bill, 2023, passed by Lok Sabha on July 27, is in the news for its lenient approach to the crime of manufacturing “not of standard quality” (NSQ) Drugs. But comparatively less attention is being paid to the adverse impact that the legislation will have on an equally serious issue, which is the regulation of pharmacies that have a key role to play in India’s drug supply. To begin...
More »SEARCH RESULT
Total Matching Records found : 977
Poverty and inequality
KEY TRENDS • Oxfam India's 2023 India Supplement report on poverty and inequality in India reveals that the gap between the rich and the poor is widening. Following the pandemic in 2019, the bottom 50 per cent of the population have continued to see their wealth chipped away. By 2020, their income share was estimated to have fallen to only 13 per cent of the national income and have less than 3...
More »Can Centralized Regulation Help Drug Quality? - Tauseef Shahidi
Livemint Recent deaths in Gambia, Uzbekistan and the US, allegedly caused by toxic Drugs made in India, has the Centre reportedly planning to centralize drug regulation. How effective will this measure be? The Central Drugs Standard Control Organization (CDSCO) is the apex regulatory body. Each state has its own regulator. The state regulators look after licencing and audit manufacturing facilities while CDSCO is responsible for approving new Drugs, imports of devices, clinical...
More »The need to make cancer Drugs affordable -Biswajit Dhar and Chetali Rao
-The Hindu With the Rajya Sabha Standing Committee on Health expressing concern over the high cost of cancer treatment, the Government invoking Section 100 of the Patents Act is a way forward The subject of the spiralling costs of cancer medicines and their implications that have frequently been highlighted the world over were dwelled on in a recent report (“Cancer Care Plan and Management”) by the Rajya Sabha’s Standing Committee on Health....
More »Price cut on TB drug to expand access
-The Hindu Business Line Agreement between Viatris, MedAccess and TBA to slash cost by 34 per cent on pretomanid A new agreement among drugmaker Viatris, MedAccess, and TB Alliance looks to reduce the price of pretomanid, a drug used to treat multidrug-resistant tuberculosis, by 34 per cent. The agreement will help expand access to this critical new treatment in more than 140 countries, including those with the highest TB burden, said a joint...
More »
